Angelini Ventures is the venture capital arm of Angelini Industries, investing €300 million globally in BioTech and HealthTech companies. The firm partners with entrepreneurs across the entire journey of company building, focusing on leveraging technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations. Angelini Ventures operates through offices in Rome, Geneva, Munich, Boston, Dubai, Singapore, Berlin, London, New York, Basel, Milan, and Paris, working with a network of innovative founders, fellow investors, and academic partners. Recent investments include Nouscom's €120M cancer immunotherapy round, MMI's $125M Series D for robotic microsurgery, and RougeTx's $58M Series A for rare bleeding disorder treatment.

Profile auto-generated from public sources — details unverified.